ProCE Banner Activity

CME

Improving Outcomes in Patients With RVO: Tailoring Treatment

Video

Experts present key data about anti-VEGF therapies for RVO, developing treatment protocols that use current therapies most effectively to improve outcomes, and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 15, 2023

Expiration: November 14, 2024

No longer available for credit.

Share

Faculty

Carl J. Danzig

Carl J. Danzig, MD

Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, Florida
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida

Arshad M. Khanani

Arshad M. Khanani, MD, MA, FASRS

Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, Nevada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

The intended audience for this educational initiative is ophthalmologists, who are clinicians responsible for the ocular evaluation and management of patients with retinal vein occlusion.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Retinal Vein Occlusion (RVO)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare current anti-VEGF therapies for RVO to select the most appropriate therapy for an individual patient

  • Develop treatment protocols in RVO that use current therapies most effectively for a particular patient and that include appropriate follow-ups to improve outcomes in patients with RVO

  • Modify an individualized treatment protocol for patients with RVO who are nonresponsive to first-line therapies and who require chronic treatment for macular edema

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Carl J. Danzig, MD

Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, Florida
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida

Carl J. Danzig, MD: consultant/advisor/speaker: Adverum, Alimera, Genentech, Kodiak Sciences, IvericBio, Regeneron.

Arshad M. Khanani, MD, MA, FASRS

Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, Nevada

Arshad M. Khanani, MD, MA, FASRS: consultant: 4D Molecular Therapeutics, AbbVie, Adverum, Aerie, Aldebaran, Allergan, Amgen, Annexin, Annexon, Apellis, Applied Genetics Technologies Corporation, Arrowhead, Ashvattha, Aviceda Therapeutics, Bausch & Lomb, Beacon Therapeutics, Broadwing Bio, Clearside, Exgenesis, EyePoint, Frontera, Genentech, Inc., Gyroscope, iLumen, Iveric Bio, Janssen, Kartos, Kato, Kodiak Sciences, Kriya, Nanoscope, Notal, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olives Bio, Opthea, Oxurion, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Thea, Unity, Vanotech, Vial; researcher: 4D Molecular Therapeutics, Adverum, Alexion, Annexon, Apellis, Exegenesis, Genentech, Inc., Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxular, Oxurion, Regenxbio, Rezolute, Roche, Unity, Vanotech.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 15, 2023, through November 14, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.